American Vanguard vs Bioceres Crop Solutions
AVD and BIOX side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AVD and BIOX compare
American Vanguard grew revenue faster over the last twelve months (−5.8% versus −17.7% for Bioceres Crop Solutions).
American Vanguard scores higher on the StockData Score (3 against 1 for Bioceres Crop Solutions), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AVD | BIOX |
|---|---|---|
| Size and price | ||
| Market cap | $25.1M | – |
| Share price | $0.879 | $0.233 |
| Change, 1 year | −82.6% | −86.6% |
| Change, 5 years | −94.5% | −98.5% |
| Beta (5Y) | 0.91 | 0.76 |
| Employees | 739 | 562 |
| StockData Score | ||
| Total score | 3 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.1× | – |
| Growth | ||
| Revenue growth (TTM) | −5.8% (better) | −17.7% |
| Revenue growth, 5Y average | 2.3% | 2.6% (better) |
| Profitability | ||
| Gross margin | 28.4% | 34.9% (better) |
| Operating margin | −5.7% (better) | −9.8% |
| Net margin | −12.0% | – |
| FCF margin | – | 27.3% |
| Return on invested capital | – | −7.4% |
| Financial health | ||
| Debt / equity | – | 10.01 |
| Interest coverage | −1.0× | −0.6× (better) |
| Current ratio | 2.02 (better) | 0.80 |
| Altman Z-score | 1.30 | – |
| Piotroski F-score | 5 | – |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 51.6% | 13.2% |
| Held by insiders | 6.2% | 73.3% |
| Insider net buying, 12 months | −$987K | – |
| Short interest, % of float | 1.1% | 2.7% |
Go deeper
- AVD stock overview
- AVD income statement
- AVD valuation and score
- BIOX stock overview
- BIOX income statement
- BIOX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.